key: cord-1047975-28e1rryy
authors: Llàcer, Pau; Manzano, Luis; Fernández, Cristina; Moreno, Mari Carmen; Núñez, Julio
title: Mid-term Prognostic Implication of hospitalized COVID-19 patients with Prior Heart Failure diagnosis
date: 2021-02-25
journal: Eur J Intern Med
DOI: 10.1016/j.ejim.2021.02.013
sha: dbdcdae99cd43397a96cc67a622f0c9861e220b4
doc_id: 1047975
cord_uid: 28e1rryy

nan

diseases, including cardiovascular disease [heart failure (HF), ischemic heart disease, hypertension, diabetes mellitus (DM)] 2,3 . Recent publications indicate that patients with prior HF represent a subgroup of higher risk of short-term adverse events 4 . However, the prognostic impact of a previous HF diagnosis beyond 1-month follow-up in patients with COVID-19 remains unknown. In this study, we aimed to evaluate the relationship between a prior diagnosis of HF and adverse clinical at mid-term follow-up in patients hospitalized for COVID-19. This is a retrospective observational study of a single center in Spain (Manises Hospital, Valencia-Spain, attending 250,000 inhabitants). This study included 225 consecutive patients admitted with COVID-19 in this center from March 12th to May 10th, 2020. The diagnosis of COVID-19 was made based on the WHO recommendations and based on a positive chain reaction of the polymerase (PCR).

Demographic data, medical history, physical examination, blood tests, chest Xray, prior and in-hospital treatments (antivirals, antibiotics, corticosteroids, ventilatory support) were collected. The previous diagnosis of HF was based on the definition proposed by the current European Society of Cardiology guidelines.

The endpoint of this study was the composite of death or readmission at midterm follow-up. Readmission definition required any unplanned in-hospital stay longer than 24 h. The follow-up started on admission, and events included those ascertained during the follow-up (including in-hospital deaths) and post-discharge.

Continuous variables were shown as mean ± standard deviation (SD) To determine the impact of HF history on outcomes, univariate and multivariable Cox proportional hazard regression models were built. Estimates of risk were presented as hazard ratios (HR). All covariates shown in Table 1 A two-tailed p-value of <0.05 was considered statistically significant for all analyzes.

All analyzes were performed with STATA 15.1 (StataCorp, 2017, Stata Statistical Software: Release 15; StataCorp, LLC, College Station, TX).

The mean age of the study sample was 68±17 years, and 43% were women.

Prior diagnosis of HF was present in 71 (31,5%) of the sample. In order of frequency, the most prevalent other comorbidities were hypertension (55%), DM2 (28%), ischemic heart disease (14%), atrial fibrillation (9%), cancer (8,9%), CKD (8,4%), COPD (4,4%) and stroke (4,4%). The clinical characteristics of the study population stratified by history of HF are listed in table 1. Patients with prior HF were older and showed a higher prevalence of other comorbidities, higher D-Dimer, troponin I, and lower hemoglobin and glomerular filtration rates. The mean left ventricular ejection fraction (LVEF) (last available measurement before hospitalization) and the median of Nterminal pro-brain natriuretic peptide (NT-proBNP) and troponin I on admission were among those with HF were 62%±12, 4294 pg/ml (2140-6448), and 111,4 ng/ml (49,2-173,5), respectively. A total of 64 patients (90.1%) had LVEF≥50%. There were no differences in COVID-19 clinical presentation between both groups. Also, there were no differences in non-invasive mechanical ventilation or oxygen supplementation with a nasal cannula. The median length of stay was higher in the HF-group (Table 1) . In this retrospective study of a cohort of patients hospitalized for COVID-19 with a high prevalence of prior HF (31% of the study sample), patients with HF had more than the two-fold increased risk of the composite of death or readmission at midterm follow-up. Interestingly, this excess of risk was not limited to hospitalization but extended to the post-discharge period, especially regarding a higher risk of new rehospitalizations.

HF has been evaluated as an independent risk factor for death in other studies, analyzing in-hospital mortality, or with follow-up of less than one month. Inciardi et al. 4 . retrospectively analyzed 99 patients hospitalized for COVID-19 pneumonia, 53 patients with previous CVD, including 21 patients with HF. Hospital mortality was 26% and higher in patients with cardiac disease than the others (36% vs. 15%, log-rank p= 0.019; relative risk: 2.35; 95% CI:1.08-5.09). In the same line, a large cohort of 6,349 patients admitted for COVID-19, 422 patients had prior HF (6.2%), and the risk of mortality among patients with HF was two-fold higher (40.0% vs. 24.9%; Odds Ratio: 2.02; 95% CI: 1.65 to 2.48; p<0.001) 5 . These data agree with our findings. However, we extended the persistence of higher risk at mid-term follow-up.

Interestingly, the risk associated with prior HF persisted after discharge, mainly by an increased risk of subsequent readmissions. The prevalence of HF in our study was higher than others 4, 5, 8 . This fact may reflect the older age and the increased cardiovascular burden of the sample here evaluated. There are no prior studies in the literature evaluating the prognostic impact of COVID-19 infection across HF status at a mid-term follow-up to the best of our knowledge.

With the present data, we cannot unravel the underlying mechanisms behind these findings: however, we may envision some of them. The baseline risk of HF patients is extremely high, especially in the first months after a decompensation. Thus, COVID-19, as it occurs with other viruses and infections, might be playing a role as a stressor and precipitating the HF decompensation, increasing the vulnerability and worse outcomes. On the other hand, there is abundant evidence demonstrating the tropism of SARS-CoV-2 for vascular/cells with a subsequent higher risk of thromboembolic event 6 . More recently, some data suggest SARS-CoV-2 may also infect cardiomyocytes as has been demonstrated in autopsies 7 , and indicated by studies reflecting and increased levels of biomarkers of myocardial injury, such as troponins 8,9 , and the presence of persistent myocardial inflammatory activity measured with magnetic resonance imaging in patients who had recovered from COVID-19 10 . Thus, further studies are warranted to confirm or not the causative role of COVID-19 on myocardial function and HF progression.

The clinical implications of this study are that COVID-19 patients with prior HF constitutes a very high-risk subgroup of adverse events at mid-term follow-up (not only limited to early in-hospital events). These findings suggest these patients should require close monitoring during the index hospitalization but also at post-discharge. Important limitations should be acknowledged. First, this is an observational retrospective and single centre study in which the risk of meaningful selection bias and residual confounding cannot be ruled out. Indeed, this is a sample of the first wave of the pandemic in which only the most severe patients were identified. Second, natriuretic peptide levels were only available in those with prior HF (based on the protocol of the centre). Third, echocardiograms were not routinely performed during hospitalization.

We reported the last LVEF available prior to COVID-19 infection.

In conclusion, in patients hospitalized with COVID-19, the prior diagnosis of HF significantly increases the risk of death or readmissions at mid-term follow-up.

This work was supported by CIBER Cardiovascular (grant numbers 16/11/00420). 

Early Transmission Dynamics in Wu han China, of Novel Coronavirus-Infected Pneumonia

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)

Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy

Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19

COVID-19 for the cardiologist: basic virology, epidemiology, cardiac manifestations, and potential therapeutic strategies

Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases

prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection

Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019Results of a Multicenter Study

Outcomes of cardiovascular magnetic resonance in patients recently recovered from coronavirus disease 2019 (COVID-19)

The authors declared no potential conflicts of interest concerning the research, authorship, and publication of this article

Values are mean ± SD, n (%), or median (interquartile range). COPD: chronic obstructive pulmonary disease; HF: heart failure; RAAS: renin angiotensin aldosterone system; MRA: mineralocorticoid receptor antagonists; PCR: polymerase chain reaction; LDH: lactate dehydrogenase; AST/GOT: aspartate aminotransferase; ALT/GPT: alanine aminotransferase; NIMV: non-invasive mechanical ventilation